The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

AC1NQXQM     (Z)-7-[(2S,3S,4S)-4-hydroxy- 2-[(E,3S)-3...

Synonyms: SureCN501141, CHEBI:28667, BML2-B08, LMFA03030004, C05964, ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of LMFA03030004


High impact information on LMFA03030004


Chemical compound and disease context of LMFA03030004


Biological context of LMFA03030004


Anatomical context of LMFA03030004


Associations of LMFA03030004 with other chemical compounds


Gene context of LMFA03030004

  • Basal measurements of urinary 11-dehydro-TXB2 and PAI-1 confirmed previous findings of enhanced levels of these parameters in NIDDM patients with macrovascular disease in comparison to age- and sex-matched controls [23].
  • Rofecoxib had no significant effect on urinary excretion of 11-dehydro TXB2, a COX-1-derived product [24].
  • Fluvastatin also lowered urinary 11-dehydro-TXB2 (1396 +/- 536 vs 1009 +/- 378 pg/mg creatinine [-27%], P = 0.0015) and von Willebrand Factor levels (1456 +/- 716 vs 1203 +/- 527 U/L [-17.4%], P = 0.0275), and a direct correlation was observed between P-selectin and 11-dehydro-TXB2 levels (r = 0.588, P = 0.0033) [25].
  • Soluble CD40L linearly correlated with 11-dehydro-TXB2 (rho = 0.67, p < 0.0001), and both were reduced after one week of aspirin (p < 0.0026), with slow recovery over 10 days after aspirin withdrawal [26].
  • Successful weight loss (0.6 kg loss/week) achieved in 5 subjects was associated with increased S(I) (+92%) and decreased CD40L (-27%), CRP (-37%), and 11-dehydro-TXB2 (-53%) (p < 0.05) [11].

Analytical, diagnostic and therapeutic context of LMFA03030004


  1. Diabetes mellitus, hypercholesterolemia, and hypertension but not vascular disease per se are associated with persistent platelet activation in vivo. Evidence derived from the study of peripheral arterial disease. Davì, G., Gresele, P., Violi, F., Basili, S., Catalano, M., Giammarresi, C., Volpato, R., Nenci, G.G., Ciabattoni, G., Patrono, C. Circulation (1997) [Pubmed]
  2. 11-Dehydrothromboxane B2: a quantitative index of thromboxane A2 formation in the human circulation. Catella, F., Healy, D., Lawson, J.A., FitzGerald, G.A. Proc. Natl. Acad. Sci. U.S.A. (1986) [Pubmed]
  3. Increased platelet activation in the chronic phase after cerebral ischemia and intracerebral hemorrhage. van Kooten, F., Ciabattoni, G., Koudstaal, P.J., Dippel, D.W., Patrono, C. Stroke (1999) [Pubmed]
  4. Abnormally high thromboxane biosynthesis in homozygous homocystinuria. Evidence for platelet involvement and probucol-sensitive mechanism. Di Minno, G., Davì, G., Margaglione, M., Cirillo, F., Grandone, E., Ciabattoni, G., Catalano, I., Strisciuglio, P., Andria, G., Patrono, C. J. Clin. Invest. (1993) [Pubmed]
  5. Increased thromboxane biosynthesis in type IIa hypercholesterolemia. Davì, G., Averna, M., Catalano, I., Barbagallo, C., Ganci, A., Notarbartolo, A., Ciabattoni, G., Patrono, C. Circulation (1992) [Pubmed]
  6. Determinants of enhanced thromboxane biosynthesis in patients with systemic lupus erythematosus. Ferro, D., Basili, S., Roccaforte, S., Di Franco, M., Cipollone, F., Ciabattoni, G., Davì, G. Arthritis Rheum. (1999) [Pubmed]
  7. Co-administration of nitric oxide-aspirin (NCX-4016) and aspirin prevents platelet and monocyte activation and protects against gastric damage induced by aspirin in humans. Fiorucci, S., Mencarelli, A., Meneguzzi, A., Lechi, A., Renga, B., del Soldato, P., Morelli, A., Minuz, P. J. Am. Coll. Cardiol. (2004) [Pubmed]
  8. Changes in prostacyclin, thromboxane A2 and F2-isoprostanes, and influence of eicosapentaenoic acid and antiplatelet agents in patients with hypertension and hyperlipidemia. Yamada, M., Omata, K., Abe, F., Ito, S., Abe, K. Immunopharmacology (1999) [Pubmed]
  9. The role of thromboxane (TX) A2 in rabbit arterial thrombosis induced by endothelial damage. Imura, Y., Terashita, Z., Nishikawa, K. Thromb. Res. (1990) [Pubmed]
  10. Modulation of aspirin-insensitive eicosanoid biosynthesis by 6-methylprednisolone in unstable angina. Cipollone, F., Ganci, A., Greco, A., Panara, M.R., Pasquale, M., Di Gregorio, D., Porreca, E., Mezzetti, A., Cuccurullo, F., Patrignani, P. Circulation (2003) [Pubmed]
  11. Insulin resistance as a determinant of platelet activation in obese women. Basili, S., Pacini, G., Guagnano, M.T., Manigrasso, M.R., Santilli, F., Pettinella, C., Ciabattoni, G., Patrono, C., Dav??, G. J. Am. Coll. Cardiol. (2006) [Pubmed]
  12. Increased thromboxane biosynthesis in essential thrombocythemia. Rocca, B., Ciabattoni, G., Tartaglione, R., Cortelazzo, S., Barbui, T., Patrono, C., Landolfi, R. Thromb. Haemost. (1995) [Pubmed]
  13. Feasibility of using [18O2]11-dehydrothromboxane B2 as an internal standard of immunoaffinity purification followed by gas chromatography/selected ion monitoring. Ishibashi, M., Ohyama, Y., Watanabe, K., Hayashi, Y., Takasaki, W., Nakagawa, A., Mizugaki, M. Chem. Pharm. Bull. (1989) [Pubmed]
  14. Difference in urinary LTE4 and 11-dehydro-TXB2 excretion in asthmatic patients. Suzuki, N., Hishinuma, T., Abe, F., Omata, K., Ito, S., Sugiyama, M., Mizugaki, M. Prostaglandins Other Lipid Mediat. (2000) [Pubmed]
  15. Determinants of platelet activation in human essential hypertension. Minuz, P., Patrignani, P., Gaino, S., Seta, F., Capone, M.L., Tacconelli, S., Degan, M., Faccini, G., Fornasiero, A., Talamini, G., Tommasoli, R., Arosio, E., Santonastaso, C.L., Lechi, A., Patrono, C. Hypertension (2004) [Pubmed]
  16. Circulating and urinary thromboxane B2 metabolites in the rabbit: 11-dehydro-thromboxane B2 as parameter of thromboxane production. Westlund, P., Kumlin, M., Nordenström, A., Granström, E. Prostaglandins (1986) [Pubmed]
  17. Monitoring of the thromboxane A2/prostacyclin ratio in the urine of patients with retinal vascular occlusion through the low-dose-aspirin therapy using the gas chromatography/selected ion monitoring method. Mizugaki, M., Hishinuma, T., Matsumura, E., Murai, Y., Yamazaki, T., Yamanobe, S., Tamai, M. Prostaglandins Other Lipid Mediat. (1999) [Pubmed]
  18. Enhanced thromboxane biosynthesis in patients with chronic obstructive pulmonary disease. The Chronic Obstructive Bronchitis and Haemostasis Study Group. Davì, G., Basili, S., Vieri, M., Cipollone, F., Santarone, S., Alessandri, C., Gazzaniga, P., Cordova, C., Violi, F. Am. J. Respir. Crit. Care Med. (1997) [Pubmed]
  19. Effects of short-term exercise on female platelet function during different phases of the menstrual cycle. Wang, J.S., Jen, C.J., Lee, H.L., Chen, H.I. Arterioscler. Thromb. Vasc. Biol. (1997) [Pubmed]
  20. Determinants of enhanced thromboxane biosynthesis in renal transplantation. Averna, M., Barbagallo, C.M., Ganci, A., Giammarresi, C., Cefalù, A.B., Sparacino, V., Caputo, F., Basili, S., Notarbartolo, A., Davì, G. Kidney Int. (2001) [Pubmed]
  21. Platelet-vessel wall interactions with third-generation oral contraceptives: no evidence of detrimental effects. Fruzzetti, F., Giannessi, D., Ricci, C., Bernini, W., Puntoni, R., Genazzani, A.R., De Caterina, R. Thromb. Haemost. (1999) [Pubmed]
  22. Intravenous bolus of prednisolone decreases 15-hydroxyeicosatetraenoic acid formation in the rat model of acid aspiration. Nagase, T., Fukuchi, Y., Teramoto, S., Jo, C., Uejima, Y., Yamaoka, M., Ishida, K., Shimizu, T., Orimo, H. Crit. Care Med. (1991) [Pubmed]
  23. Influence of metabolic control on thromboxane biosynthesis and plasma plasminogen activator inhibitor type-1 in non-insulin-dependent diabetes mellitus. Davì, G., Belvedere, M., Vigneri, S., Catalano, I., Giammarresi, C., Roccaforte, S., Consoli, A., Mezzetti, A. Thromb. Haemost. (1996) [Pubmed]
  24. Comparative inhibitory activity of rofecoxib, meloxicam, diclofenac, ibuprofen, and naproxen on COX-2 versus COX-1 in healthy volunteers. Van Hecken, A., Schwartz, J.I., Depré, M., De Lepeleire, I., Dallob, A., Tanaka, W., Wynants, K., Buntinx, A., Arnout, J., Wong, P.H., Ebel, D.L., Gertz, B.J., De Schepper, P.J. Journal of clinical pharmacology. (2000) [Pubmed]
  25. Fluvastatin reduces soluble P-selectin and ICAM-1 levels in hypercholesterolemic patients: role of nitric oxide. Romano, M., Mezzetti, A., Marulli, C., Ciabattoni, G., Febo, F., Di Ienno, S., Roccaforte, S., Vigneri, S., Nubile, G., Milani, M., Davì, G. J. Investig. Med. (2000) [Pubmed]
  26. Thromboxane-dependent CD40 ligand release in type 2 diabetes mellitus. Santilli, F., Davì, G., Consoli, A., Cipollone, F., Mezzetti, A., Falco, A., Taraborelli, T., Devangelio, E., Ciabattoni, G., Basili, S., Patrono, C. J. Am. Coll. Cardiol. (2006) [Pubmed]
  27. Differential suppression of thromboxane biosynthesis by indobufen and aspirin in patients with unstable angina. Cipollone, F., Patrignani, P., Greco, A., Panara, M.R., Padovano, R., Cuccurullo, F., Patrono, C., Rebuzzi, A.G., Liuzzo, G., Quaranta, G., Maseri, A. Circulation (1997) [Pubmed]
  28. Dissociation of platelet activation and spontaneous myocardial ischemia in unstable angina. Vejar, M., Fragasso, G., Hackett, D., Lipkin, D.P., Maseri, A., Born, G.V., Ciabattoni, G., Patrono, C. Thromb. Haemost. (1990) [Pubmed]
  29. In vivo prostanoid formation during acute renal allograft rejection. Tönshoff, B., Busch, C., Schweer, H., Schärer, K., Seyberth, H.W. Nephrol. Dial. Transplant. (1993) [Pubmed]
WikiGenes - Universities